Limits...
A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections.

Knitsch W, Vincent JL, Utzolino S, François B, Dinya T, Dimopoulos G, Özgüneş İ, Valía JC, Eggimann P, León C, Montravers P, Phillips S, Tweddle L, Karas A, Brown M, Cornely OA - Clin. Infect. Dis. (2015)

Bottom Line: The estimated odds ratio showed that patients with a positive (1,3)-β-d-glucan (ßDG) result were 3.66 (95% confidence interval, 1.01-13.29) times more likely to have confirmed IC than those with a negative result.It does provide some support for using ßDG to identify patients at high risk of IC.NCT01122368.

View Article: PubMed Central - PubMed

Affiliation: Department of General, Visceral and Transplantation Surgery, Hanover Medical School.

No MeSH data available.


Related in: MedlinePlus

Patient flow through the study. In the full analysis set (FAS), 30.7% of patients had either violated the protocol (10.4% had received concurrent antifungal agents and 12.9% were outside the drug study window) or had received treatment for <3 days (11.6%). Abbreviations: IC, invasive candidiasis; IDRB, independent data review board; PPS, per-protocol set.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4643488&req=5

CIV707F1: Patient flow through the study. In the full analysis set (FAS), 30.7% of patients had either violated the protocol (10.4% had received concurrent antifungal agents and 12.9% were outside the drug study window) or had received treatment for <3 days (11.6%). Abbreviations: IC, invasive candidiasis; IDRB, independent data review board; PPS, per-protocol set.

Mentions: The study was conducted at 53 centers across 17 countries. Participant flow is shown in Figure 1. The FAS comprised 241 patients, 124 randomized to placebo and 117 to micafungin (100 mg/d); baseline characteristics are provided in Table 1.Table 1.


A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections.

Knitsch W, Vincent JL, Utzolino S, François B, Dinya T, Dimopoulos G, Özgüneş İ, Valía JC, Eggimann P, León C, Montravers P, Phillips S, Tweddle L, Karas A, Brown M, Cornely OA - Clin. Infect. Dis. (2015)

Patient flow through the study. In the full analysis set (FAS), 30.7% of patients had either violated the protocol (10.4% had received concurrent antifungal agents and 12.9% were outside the drug study window) or had received treatment for <3 days (11.6%). Abbreviations: IC, invasive candidiasis; IDRB, independent data review board; PPS, per-protocol set.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4643488&req=5

CIV707F1: Patient flow through the study. In the full analysis set (FAS), 30.7% of patients had either violated the protocol (10.4% had received concurrent antifungal agents and 12.9% were outside the drug study window) or had received treatment for <3 days (11.6%). Abbreviations: IC, invasive candidiasis; IDRB, independent data review board; PPS, per-protocol set.
Mentions: The study was conducted at 53 centers across 17 countries. Participant flow is shown in Figure 1. The FAS comprised 241 patients, 124 randomized to placebo and 117 to micafungin (100 mg/d); baseline characteristics are provided in Table 1.Table 1.

Bottom Line: The estimated odds ratio showed that patients with a positive (1,3)-β-d-glucan (ßDG) result were 3.66 (95% confidence interval, 1.01-13.29) times more likely to have confirmed IC than those with a negative result.It does provide some support for using ßDG to identify patients at high risk of IC.NCT01122368.

View Article: PubMed Central - PubMed

Affiliation: Department of General, Visceral and Transplantation Surgery, Hanover Medical School.

No MeSH data available.


Related in: MedlinePlus